CrystalGenomics, Inc.

083790.KQ

083790.KQCrystalGenomics, Inc. KR flag

KOSDAQ

1,999.00

KRW

-31.00

(-1.53%)

153.71BMarket Cap

May 12Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

KR7083790006

Return %

Stock

S&P500

-35.83

6.57

-63.12

22.75

-79.25

93.55

Use logarithmic scale

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	106.11	132.62	109.98	132.17	289.8	236.02	250.64	233.78	378.9	618.29	62.46	65.91	- -	94.39
Basic EPS, GAAP	-336.5	-315.41	-289.29	-104.47	-43.48	-166.24	124.67	-627.33	-123.33	-232	-345	-661	- -	-670.76
Free Cash Flow per Basic Share	-189.18	-194.53	-94.78	-109.98	-179.7	-178.03	-27.78	-130.58	-317.68	-322.74	-564.9	-756.18	- -	-465.79
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	16.3	- -	- -	- -	- -	- -
Book Value per Share	-1,420.47	-1,666.4	-1,710.12	-1,605.09	-1,516.05	-1,637.19	-1,264.44	-1,791.22	820.65	892.71	555.85	829.05	- -	324.24
Tangible Book Value per Share	363.7	806.75	1,208.01	1,426.7	1,520.93	1,685.47	3,292.6	3,460.5	2,618.95	2,983.47	2,673.86	1,940.34	- -	1,458.67
Basic Weighted Avg Shares	35	36	41	46	50	52	55	60	80	69	69	74	- -	77
Sales/Revenue/Turnover	3,719	4,796	4,536	6,136	14,525	12,175	13,887	14,007	30,223	42,376	4,321	4,879	7,253	7,253
Operating Margin (%)	-193.88	-125.92	-159.37	-65.05	-28.14	-52.66	12.65	-75.39	-33.55	-28.82	-553.94	-644.41	-530.62	-530.62
Depreciation Expense	1,657	1,402	1,362	1,318	1,698	1,220	1,259	1,846	4,916	2,995	3,480	3,199	4,250	4,250
Net Income, GAAP	-11,794	-11,406	-11,931	-4,850	-2,179	-8,575	6,908	-37,585	-9,838	-15,901	-23,869	-48,924	-51,544	-51,544
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	3.36	- -	- -	- -	- -	- -	- -	- -
Profit Margin (%)	-317.13	-237.82	-263.05	-79.04	-15	-70.43	49.74	-268.34	-32.55	-37.52	-552.35	-1,002.81	-710.63	-710.63
Working Capital	-4,140	6,177	351	-523	-542	17,526	156,500	103,612	109,442	78,452	18,017	1,104	-4,134	-4,134
LT Debt	500	32,047	13,512	9,459	1,863	7,800	31,286	12,537	14,763	24,399	20,508	29,889	42,396	42,396
Total Equity	22,374	36,164	55,028	73,639	83,265	91,587	184,467	225,217	220,415	214,626	193,423	145,293	120,799	120,799
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	1.02	- -	- -	- -	- -	- -	- -	- -
Return on Capital (%)	- -	- -	- -	- -	- -	- -	-17.05	- -	- -	- -	- -	- -	- -	- -
Return on Common Equity (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	-25.11	-47.91	-98.03	-119.48	-119.48

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	29.85%	25.55%	48.67%
Net Income, GAAP	-49.74%	29.65%	5.36%
Free Cash Flow	72.91%	59.01%	-36.05%
Total Cash Common Dividend	- -	- -	93.82%
Total Equity	12.4%	-11.28%	-16.86%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Dr. Joong-Myung Cho Ph.D.
Full Time Employees: 65
Sector: Healthcare
Industry: Biotechnology
Address: Tower A, Korea Bio Park Seongnam-si South Korea 463-400
IPO Date: Jan 6, 2006
Website: cgxinc.com
Similar Companies: Relief Therapeutics Holding AG (RLFTD)
Pharmicell Co., Ltd. (005690.KS)
NRx Pharmaceuticals, Inc. (NRXP)
Albert Labs International Corp. (ABRT.CN)
Clearmind Medicine Inc. (CMND)
GeoVax Labs, Inc. (GOVX)
Business: CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial. In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services. The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was founded in 2000 and is headquartered in Seongnam, South Korea.

	Jun'24	Sep'24	Dec'24
Total Current Assets	49,374	47,674	75,802
Accounts Receivable, Net	1,477	2,421	9,345
Cash, Cash Equivalents & STI	42,016	38,899	53,564
Inventories	2,118	2,501	9,181
Total Current Liabilities	62,182	60,822	79,936
Payables & Accruals	- -	- -	- -
ST Debt	4,054	3,103	11,061
Deferred Revenue	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	- -	- -	- -	- -	- -
2023	- -	- -	- -	- -	- -
2024	- -	- -	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	-41	-87	-57	- -	-345
2023	-64	-473	284	- -	-661
2024	-98	-185	-96	- -	- -

	Jun'24	Sep'24	Dec'24
ST Debt	4,054	3,103	11,061
LT Borrowings	34,361	35,800	42,200
LT Finance Leases	231	135	196
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	77	77	77
Market Capitalization	203,820	187,885	184,811

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	106.11	132.62	109.98	132.17	289.8	236.02	250.64	233.78	378.9	618.29	62.46	65.91	- -	94.39
Basic EPS, GAAP	-336.5	-315.41	-289.29	-104.47	-43.48	-166.24	124.67	-627.33	-123.33	-232	-345	-661	- -	-670.76
Free Cash Flow per Basic Share	-189.18	-194.53	-94.78	-109.98	-179.7	-178.03	-27.78	-130.58	-317.68	-322.74	-564.9	-756.18	- -	-465.79
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	16.3	- -	- -	- -	- -	- -
Book Value per Share	-1,420.47	-1,666.4	-1,710.12	-1,605.09	-1,516.05	-1,637.19	-1,264.44	-1,791.22	820.65	892.71	555.85	829.05	- -	324.24
Tangible Book Value per Share	363.7	806.75	1,208.01	1,426.7	1,520.93	1,685.47	3,292.6	3,460.5	2,618.95	2,983.47	2,673.86	1,940.34	- -	1,458.67
Basic Weighted Avg Shares	35	36	41	46	50	52	55	60	80	69	69	74	- -	77
Sales/Revenue/Turnover	3,719	4,796	4,536	6,136	14,525	12,175	13,887	14,007	30,223	42,376	4,321	4,879	7,253	7,253
Operating Margin (%)	-193.88	-125.92	-159.37	-65.05	-28.14	-52.66	12.65	-75.39	-33.55	-28.82	-553.94	-644.41	-530.62	-530.62
Depreciation Expense	1,657	1,402	1,362	1,318	1,698	1,220	1,259	1,846	4,916	2,995	3,480	3,199	4,250	4,250
Net Income, GAAP	-11,794	-11,406	-11,931	-4,850	-2,179	-8,575	6,908	-37,585	-9,838	-15,901	-23,869	-48,924	-51,544	-51,544
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	3.36	- -	- -	- -	- -	- -	- -	- -
Profit Margin (%)	-317.13	-237.82	-263.05	-79.04	-15	-70.43	49.74	-268.34	-32.55	-37.52	-552.35	-1,002.81	-710.63	-710.63
Working Capital	-4,140	6,177	351	-523	-542	17,526	156,500	103,612	109,442	78,452	18,017	1,104	-4,134	-4,134
LT Debt	500	32,047	13,512	9,459	1,863	7,800	31,286	12,537	14,763	24,399	20,508	29,889	42,396	42,396
Total Equity	22,374	36,164	55,028	73,639	83,265	91,587	184,467	225,217	220,415	214,626	193,423	145,293	120,799	120,799
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	1.02	- -	- -	- -	- -	- -	- -	- -
Return on Capital (%)	- -	- -	- -	- -	- -	- -	-17.05	- -	- -	- -	- -	- -	- -	- -
Return on Common Equity (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	-25.11	-47.91	-98.03	-119.48	-119.48

Year	Q1	Q2	Q3	Q4	FY
2022	8,202	5,503	5,080	16,844	4,321
2023	1,849	1,361	613	-13,579	4,879
2024	709	2,180	1,629	2,735	7,253

CrystalGenomics, Inc.

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Working Capital

Quarterly Dividends Per Share

Year

Quarterly Earnings Per Share

Year

Capital Structure

Quarterly Revenue

Year